Neuroendocrine carcinoma (NEC) can be an aggressive disease with locoregional and distant metastasis. We present this article (1) to highlight the typical presentation of NEC in head and neck primary sites such as the parotid gland, paranasal sinuses, and supraglottis and (2) to discuss the prognosis of these tumors based on their histologic subtype and stage. We base our comments on the findings of our retrospective review of the cases of 16 adults-10 men and 6 women, aged 43 to 88 years (mean: 65.8)-who had been diagnosed with pathologically confirmed NEC of the head and neck. Analysis of subtypes revealed that 11 of these patients (68.8%) had presented with poorly differentiated NEC, 4 (25.0%) with moderately differentiated NEC, and 1 (6.3%) with well-differentiated NEC. The most common primary sites were the salivary glands (n = 5; 31.3%), paranasal sinuses (n = 4, 25.0%), and larynx (n = 4). There was no statistically significant difference in survival at 24 months between the patients with moderately differentiated NEC and those with poorly differentiated NEC (37.5 vs. 35.4%; p = 0.86); at the end of the study period, the patient with well-differentiated NEC was still living, 129 months after diagnosis. Taken together, patients with stage I, II, and III disease had a combined survival of 77.8% at 12 months, which was significantly higher (p = 0.023) than the 57.1% survival at 12 months for patients with stage IV disease.
Introduction
Neuroendocrine carcinoma (NEC) is a composite tumor of the nervous and endocrine systems that has a capacity to release neuropeptides into the systemic circulation. On electron microscopy, the tumor cells are noted to contain membrane-bound, electron-dense neurosecretory granules. On immunohistochemical staining, NEC may be positive for chromogranin, synaptophysin, cytokeratin AE1/AE3, neuron-specific enolase, and others.
Primary NEC of the head and neck is exceedingly rare. Nevertheless, it is imperative to correctly differentiate it from the much more common squamous cell carcinomas because their treatments differ dramatically. Unfortunately, because of NEC's rarity, it has been difficult to categorize its clinical and histopathologic behaviors.
There has been some debate among pathologists about how to classify NECs of the head and neck (table 1). In 1993, the World Health Organization (WHO) classified laryngeal NEC into three categories: typical carcinoid, atypical carcinoid, and small-cell carcinoma. 1 However, there was a later push to abandon these terms because some clinicians found their meanings ambiguous. For example, in 2002, Mills argued that the term atypical carcinoid implies a close relationship with the more indolent typical carcinoid, although in reality the atypical carcinoids are aggressive, highly metastatic tumors that merit a more aggressive treatment approach. 2 Mills also noted that unlike atypical carcinoids, typical carcinoids are not associated with cigarette smoking and that they rarely display cytologic atypia. Therefore, he proposed the terms well-differentiated, moderately differentiated, and poorly differentiated.
Wick classified the three subtypes as grade I, grade II, and grade III NEC, respectively. 3 As the debate over NeuroeNdocriNe carciNoma of the head aNd Neck: a 20-year case series nomenclature continues, we will use the Mills classification in the remainder of this article.
We describe our case series of NEC at a single comprehensive cancer center, and we discuss the clinical presentation, histopathologic characteristics, and prognosis.
Patients and methods
We searched the surgical pathology database at The Ohio State University Medical Center to identify all cases of NEC of the head and neck in adults who had presented between Jan. 1, 1988, and Jan. 1, 2008. The pathology slides from these cases were reexamined by a head and neck pathologist. Inclusion criteria included light microscopic identification of malignant small round cell tumors by positive staining with the neuroendocrine markers chromogranin and synaptophysin. Cases were included only if there had been a biopsy-proven diagnosis; findings on fine-needle aspiration cytology were insufficient. Exclusion criteria included cases of metastatic NEC, paraganglioma, Merkel cell tumor, olfactory neuroblastoma, sinonasal undifferentiated carcinoma, and basaloid squamous carcinoma.
Our initial search identified 28 patients with NEC of the head and neck. However, further histopathologic review determined that 12 of these cases were not true NECs; although they stained positive with NEC immunohistochemical markers, they lacked the morphology of any of the three NEC subtypes. Most of the excluded pathologies were olfactory neuroblastomas, sinonasal undifferentiated carcinomas, and basaloid squamous carcinomas. The remaining 16 patients whose cases qualified for study eligibility included 10 men and 6 women, aged 43 to 88 years (mean: 65.8).
In addition to demographic data, we compiled information on the history, treatment, and various clinical and prognostic features of these cases. Survival data were estimated according to the Kaplan-Meier method from the time of the initial presentation to the time of death.
An Institutional Review Board exemption was obtained from the Office of Responsible Research at The Ohio State University.
Results
Of the 16 patients, 11 (68.8%) had smoked cigarettes (mean pack-years: 50.5; range: 15 to 116). Seven (43.8%) had used alcohol, including 3 (18.8%) who were described as alcohol abusers. Five patients (31.3%) had a history of a non-NEC cancer-3 that had originated in the skin, 1 in the oropharynx, and 1 in the epiglottis.
The most common sites of primary origin were the salivary glands, the paranasal sinus, and the supraglottis (table 2). Of the 16 NECs, 11 were poorly differentiated, 4 were moderately differentiated, and 1 was well differentiated.
The clinical presentation varied according to the primary tumor's location. Among the 4 patients who had a supraglottic laryngeal primary, 2 presented with dysphagia, 1 with odynophagia, and 1 with voice changes. Among the 4 with a paranasal sinus tumor, 2 presented with headache, 1 with nasal discharge, and 1 with facial numbness. One patient with a poorly differentiated T2N0M0 NEC of the parotid gland presented with a paraneoplastic syndrome that included symptoms of gait ataxia, dysarthria, and visual disturbances.
Rates of metastasis varied among patients according to the specific type of NEC. Among the 11 patients with poorly differentiated NEC, tumor had spread to the regional lymph nodes in 8 patients, while another patient experienced distant metastases to the liver and pancreas. In the 4 patients with moderately differentiated NEC, metastasis to the regional lymph nodes occurred in 3; no distant metastasis was seen in this group. No regional or distant metastasis occurred in the 1 patient with well-differentiated NEC. Treatment regimens consisted of surgery alone, chemo-and/or radiotherapy without surgery, or chemoand/or radiotherapy with surgery (table 3). One patient who had presented with advanced disease died before treatment could be initiated.
Kaplan-Meier curves were used to estimate survival, which ranged from 0 to 129 months. The 4 patients with moderately differentiated NEC fared slightly better at 24 months (37.5% survival) than did those with poorly differentiated NEC (35.4%), but the difference was not statistically significant (p = 0.86) ( figure 1) . At the end of the study period, the patient with well-differentiated NEC was still living, 129 months following diagnosis.
Survival was also compared with tumor stage at presentation (figure 2). Because our sample size was so small, we divided patients into two groups based on how far advanced their disease was; one group was made up of those who had presented before stage IV (i.e., at stages I, II, or III), and the other was represented by those who had presented with stage IV NEC. At 12 months after diagnosis, survival among those who had presented with a stage I, II, or III tumor was significantly better than it was in those with stage IV disease (77.8 vs. 57.1%; p = 0.023).
Discussion
As an exceedingly rare entity, NEC typically presents diagnostic and therapeutic challenges. As shown by our initial record review, patients may be initially misdiagnosed. Pathologic confirmation of NEC requires the application of appropriate neuroendocrine marker immunohistology to exclude other malignant small round cell neoplasms that may be considered in the differential diagnosis, including olfactory neuroblastoma, sinonasal undifferentiated carcinoma, basaloid squamous carcinoma, poorly differentiated adenoid cystic carcinoma, and non-Hodgkin lymphoma. Well-differentiated NEC. Well-differentiated NEC is the rarest NEC subtype. According to Ferlito et al, only 43 cases of head and neck NEC had been reported as of 2006; most of those had involved the supraglottic larynx. 4 Microscopically, well-differentiated NECs are identical to carcinoids that occur throughout the rest of the body, notably in the small bowel, appendix, and liver. Carcinoid syndrome has been reported in only 1 case of laryngeal NEC, which occurred after the tumor had metastasized to the liver. 5 On pathologic review, these tumors typically grow in nests and cords with cellular uniformity and a characteristic salt-and-pepper chromatin pattern. There is abundant eosinophilic cytoplasm, but mitotic figures, pleomorphism, and necrosis are usually absent. 6 These tumors were once thought to be indolent, an inference that was based on their presumed tie to carcinoid tumors elsewhere in the body. However, recent data have shown that locoregional metastasis is not uncommon, with reported rates ranging from 30.7 to 33%. 7, 8 While it is agreed that surgical resection of the primary tumor is the mainstay of treatment, there is disagreement over the utility of elective neck dissection. 4 Five-year survival for patients with well-differentiated NEC of the larynx has been reported at 48%. 9 The 1 patient in our series who had well-differentiated NEC presented with a stage I glottic tumor. He underwent surgical resection, and at the end of the study period, he was still alive, 129 months after his diagnosis.
Moderately differentiated NEC. Moderately differentiated NEC is the most common non-squamous cell cancer of the larynx. 5 Still, as of 2005, only 350 cases had been reported, most of which had arisen in the supraglottis. 10 The reported male-to-female ratio is 3-to-1, and most patients have been heavy smokers. 11 Like the well-differentiated subtype, moderately differentiated NEC grows in nests and cords, albeit in a less organized manner. Moderately differentiated NEC can also be distinguished by increased mitotic activity, nuclear irregularity, pleomorphism, and focal necrosis.
As is the case with well-differentiated NEC, surgery is the mainstay of treatment for moderately differentiated NEC. 4 In a 1991 literature review, Woodruff and Senie reported that radiation and chemotherapy conferred no benefit. 12 Woodruff and Senie also reported survival rates of 48 and 30% at 5 and 10 years, respectively. 12 They found that these tumors had metastasized to neck nodes in 43% of cases and to distant sites in 44%, findings that illustrate the aggressive nature of these tumors. Our small study demonstrated 37.5% survival at 24 months for patients with moderately differentiated NEC.
Poorly differentiated NEC. Poorly differentiated NEC is the most common NEC subtype in the head and neck. While it is also known as small-cell carcinoma, when it occurs in the lung it is known as oat-cell carcinoma. It is highly malignant and more aggressive than the welland moderately differentiated subtypes.
Gnepp et al reported that 90% of patients with laryngeal poorly differentiated NEC will experience a metastasis at some point in their illness, most likely to the cervical lymph nodes, liver, lung, or bone. 13 The same study found that the prognosis was dismal, with 2-and 5-year survival rates of only 16% and 5%, respectively. Poorly differentiated NEC is the most common NEC subtype in the salivary glands, accounting for 2% of all malignant parotid gland tumors and 3.5% of minor salivary gland malignancies. 2 Compared with salivary gland poorly differentiated NECs, laryngeal tumors carry a better prognosis, with 2-and 5-year survival rates of 70 and 46%, respectively. 14 In our study, 35.4% of patients with poorly differentiated NEC at any location survived to 24 months. Metastases from salivary poorly differentiated NECs disseminate hematogenously, and they rarely give rise to cervical lymphadenopathy. 14 The treatment of poorly differentiated NEC historically consisted of radiation and/or chemotherapy. 13 Recently, however, researchers at the MD Anderson Cancer Center showed that in cases of NEC of the paranasal sinuses, surgery and radiation therapy yielded similar control rates and that the addition of chemotherapy was a further predictor of control. 15 In conclusion, NEC often presents with regional and/ or distant metastasis. The correct pathologic identification of these tumors is necessary because the particular subtype could dictate treatment. It is especially imperative to distinguish poorly differentiated NECs from the well-and moderately differentiated subtypes, as well as from squamous cell carcinoma, because surgery is not the mainstay of treatment for poorly differentiated NEC. Well-differentiated NEC is associated with a better prognosis than moderately differentiated NEC, which in turn has a better prognosis than poorly differentiated NEC, although these differences were not significant in our case series. Survival is related to the stage at presentation; patients who present earlier have a better prognosis.
The small size of our case series (N = 16) was a major limitation of this investigation, and therefore it was difficult to draw statistically significant conclusions. Treatment decisions for our patients were made on an individual basis and not according to any predetermined criteria; future studies might prospectively compare different treatment arms (e.g., surgical resection vs. chemotherapy/radiation) in an effort to draw reliable conclusions. It would be beneficial to conduct a multiinstitutional study in order to gather sufficient patients to design a randomized controlled trial, which might elicit further understanding of this disease.
